Robinson Bradshaw

Topic: Illumina

Life Technologies Fires Latest Sequencing Salvo

Another week, another drop in the cost of whole-genome sequencing. The latest announcement comes from Life Technologies, which yesterday announced the launch of its SOLiD 4 sequencing system. The details of the announcement are well-covered by GenomeWeb and Matthew Herper of Forbes.com. In brief, the SOLiD 4 generates 100 gigabases of data per run at […]

Meet the New deCODE, Same as the Old deCODE?

When deCODE genetics declared bankruptcy last fall it made a big splash. Geneticists pondered the future of the Icelandic biotechnology company’s one-of-a-kind genetic database and research platform, while investors and creditors wondered if they were going to be left out in the cold. The initial bankruptcy buzz gave way over the past several months to […]

GLR Update: In The Battle for Sequencing Supremacy, is 128 > $10,000?

The biggest industry developments last week were being announced at J.P. Morgan’s 28th Annual Healthcare Conference in San Francisco. The Genomics Law Report covered Illumina’s announcement of its new next-generation genomic sequencing machine (Another Stop on the Road to the $1,000 Genome), the HiSeq 2000, which promises to sequence an entire genome in one week […]

Another Stop on the Road to the $1,000 Genome

The latest stop on the road to the $1,000 genome? San Francisco, CA, where J.P. Morgan’s 28th Annual Healthcare Conference is in full swing. There is an abundance of real-time Twitter coverage from the conference, but certain announcements warrant a more detailed discussion. The announcement generating the biggest buzz today came from Illumina, Inc., whose […]

deCODE Declares. Now What?

If you’re a regular reader of the Genomics Law Report – or the Wall Street Journal for that matter – by now you have probably heard the news: deCODE genetics, Inc. has filed for Chapter 11 Bankruptcy protection. Given deCODE’s recent financial struggles, this latest development is hardly a surprise. Indeed, two months ago, we […]

Completing the Personal Genomics Toolkit

The big news buzzing through the world of genomics this afternoon is the publication of a paper in the journal Science announcing the production of three whole-genome sequences at an average materials cost of $4,400. The work was performed by the third-generation sequencing company Complete Genomics Incorporated, along with researchers from George Church’s lab at Harvard […]

Make Room for Big Blue: IBM the Latest (and Largest) Entrant in the Race for the $1,000 Genome

The quest for the $1,000 genome—viewed by many as the point at which whole-genome sequencing will become cost-effective and widely available—is a fierce competition populated by a cast of start-ups and specialized genomics companies. The most well-known entrants in the next-generation sequencing market are companies such as Oxford Nanopore, Pacific Biosciences and Complete Genomics; names that […]

Leveraging the Crowd to Understand Your Genome

Earlier this week Peter Aldhous of NewScientist magazine recounted an unusual experience with DTC genomics provider Decode Genetics. In reviewing his genetic data on the deCODEme website, Aldhous uncovered what appeared to be significant and bizarre errors in his mitochondrial DNA. Aldhous turned to Blaine Bettinger, The Genetic Genealogist, for help in diagnosing the problem […]

Will Funding Break Through the Bioinformatics Bottleneck?

Earlier this month, the NIH announced the renewal of a grant program that awards up to $275,000 over two years to academic institutes, small businesses, non-profits and other groups, to support research aimed at developing new ways of managing, manipulating and interpreting genomic and other biological data. But the utility and necessity of such grants […]

Whole-Genome Sequencing and Gene Patents Coexist (For Now)

In a recent post, John Conley analyzed the ACLU’s lawsuit challenging Myriad Genetics’ patents on the BRCA-1 and BRCA-2 “breast and ovarian cancer susceptibility” genes. Several readers responded with the same general inquiry: if an individual undergoes a whole-genome sequence analysis, will the individual (or the company providing the sequence) be required to pay royalties to […]